A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
Recruiting · Phase 2 · NCT05389293
Conditions: Follicular Lymphoma, Lymphoma
At a glance
- Research payments reported, 2025
- $1.7M
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 152
About the trial
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Tested
- Mosunetuzumab (drug), Zanubrutinib (drug)
- Dates
- Started 2022-05-27; completion 2027-12
- Results posted
- Not yet
The purpose of this study is to find out if mosunetuzumab is an effective treatment in people with follicular lymphoma that was recently diagnosed and have not yet received any treatments for their disease.
From ClinicalTrials.gov, last updated 2026-08-10. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines USA, Inc. reported $1.7M in research payments for this study in 2025 (4 payments).
Products named: Brukinsa
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Memorial Sloan Kettering Cancer Center $1.7M
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.